Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinamide N-methyltransferase (NNMT) is a cytoplasmic enzyme that catalyzes the methylation of nicotinamide (NAM), using S-adenosylmethionine (SAM) as the methyl donor. This process plays a significant role in cellular metabolism, methylation balance, and disease processes, including metabolic diseases, liver disease, and cancer. NNMT's activity links the methionine cycle with NAD+ metabolism, impacting both energy homeostasis and epigenetic regulation. It is considered a therapeutic target for conditions where its overexpression or activity contributes to disease pathology.
Inhibition of NNMT enzymatic activity, leading to increased NAM and SAM levels and altered methylation patterns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinamide N-methyltransferase (NNMT).